Lebrikizumab treatment in adults with asthma.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Many patients with asthma have uncontrolled disease despite treatment with inhaled glucocorticoids. One potential cause of the variability in response to treatment is heterogeneity in the role of interleukin-13 expression in the clinical asthma phenotype. We hypothesized that anti-interleukin-13 therapy would benefit patients with asthma who had a pretreatment profile consistent with interleukin-13 activity.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): N Engl J Med

Title: The New England journal of medicine

Publisher: Massachusetts Medical Society

ISSN (Electronic): 1533-4406

ISSN (Print): 0028-4793

Publication date (Electronic): Sep 22 2011

Volume: 365

Issue: 12

Affiliations

[1 ] Allergy Medical Clinic, Los Angeles, California, USA.

Article

DOI: 10.1056/NEJMoa1106469

PubMed ID: 21812663

SO-VID: 183bc312-a1d2-4fcc-9844-095f13eee525

History

Data availability:

Comments

Comment on this article

scite_

0

Smart Citations

0

Citing PublicationsSupportingMentioningContrasting

View Citations

See how this article has been cited at scite.ai

scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.